Table 3.

Hazard ratios with 95% confidence intervals, multivariate models

Reference: rivaroxaban	Apixaban	P‐value	Dabigatran	P‐value
Ischaemic stroke	1.06 [0.68–1.64]	0.808	1.18 [0.70–2.01]	0.535
All stroke	0.89 [0.60–1.31]	0.557	1.01 [0.62–1.64]	0.981
Systemic embolism	0.59 [0.15–2.26]	0.441	1.54 [0.31–7.60]	0.596
Death, cardiovascular	0.92 [0.72–1.17]	0.476	0.71 [0.50–1.02]	0.065
Pulmonary embolism	0.19 [0.06–0.56]	0.003	n/a
Transient ischaemic attack	0.75 [0.38–1.49]	0.413	0.63 [0.22–1.81]	0.390
Myocardial infarction	1.67 [1.02–2.71]	0.040	0.73 [0.32–1.68]	0.465
All‐cause mortality	0.82 [0.68–0.99]	0.042	0.65 [0.49–0.86]	0.003
Composite A a	0.98 [0.65–1.49]	0.941	1.18 [0.71–1.96]	0.517
Composite B b	0.85 [0.61–1.19]	0.340	0.98 [0.64–1.51]	0.936
Haemorrhagic stroke	0.53 [0.24–1.15]	0.106	0.43 [0.12–1.53]	0.194
Gastrointestinal bleeding	0.68 [0.46–0.99]	0.045	1.03 [0.63–1.68]	0.907
Other major bleeds	0.67 [0.49–0.91]	0.010	0.63 [0.40–0.99]	0.045
All bleeds (composite)	0.66 [0.52–0.83]	<0.001	0.74 [0.54–1.02]	0.067

^aIschaemic stroke + systemic embolism

^bAll stroke + transient ischaemic attack + systemic embolism